MedTrace Logo

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

NCT01086761 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with wet Age Related Macular Degeneration.

Conditions

Interventions

BIOLOGICAL

MP0112

Single intravitreal injection of MP0112 in the study eye.

Sponsors & Collaborators

  • Molecular Partners AG

    collaborator INDUSTRY

  • Allergan

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Czechia
  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01086761 on ClinicalTrials.gov